22,285 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 22,285 shares of the specialty pharmaceutical company’s stock, valued at approximately $780,000. GSA Capital Partners LLP owned about 0.07% of Collegium Pharmaceutical at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Rubric Capital Management LP increased its stake in Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after acquiring an additional 157,743 shares during the period. Emerald Advisers LLC increased its holdings in shares of Collegium Pharmaceutical by 1.3% during the second quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company’s stock worth $24,766,000 after buying an additional 11,074 shares in the last quarter. Geode Capital Management LLC raised its position in Collegium Pharmaceutical by 1.9% in the second quarter. Geode Capital Management LLC now owns 780,243 shares of the specialty pharmaceutical company’s stock valued at $23,075,000 after purchasing an additional 14,709 shares during the last quarter. Millennium Management LLC boosted its position in Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Collegium Pharmaceutical by 13.8% during the second quarter. Bank of America Corp DE now owns 514,807 shares of the specialty pharmaceutical company’s stock worth $15,223,000 after purchasing an additional 62,274 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $60.00 price target (up previously from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.40.

Collegium Pharmaceutical Stock Performance

COLL opened at $45.00 on Friday. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $50.79. The company has a market cap of $1.42 billion, a price-to-earnings ratio of 27.95 and a beta of 0.64. The company’s fifty day moving average price is $46.97 and its two-hundred day moving average price is $41.71. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71.

Insider Activity

In related news, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the transaction, the director owned 52,629 shares of the company’s stock, valued at $2,475,141.87. The trade was a 6.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Scott Dreyer sold 17,600 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president directly owned 103,613 shares of the company’s stock, valued at $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.